Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Lanadelumab SC PFS vs Autoinjector
NCT03918239Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lanadelumab in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration at 2664 hours, Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity at 2664 hours and 6 more. Started May 2019; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03918239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918239.